Journal Watch · Nature Reviews Cancer · 2026
Targeting phagocytosis checkpoints for cancer immunotherapy.
We also offer recommendations for enhancing the efficacy and safety of this approach in future work.
TL;DR
We also offer recommendations for enhancing the efficacy and safety of this approach in future work.
Key findings
- In this Review, we examine the evidence supporting phagocytic checkpoints as targets for cancer therapy, while highlighting current challenges associated with this therapeutic strategy.
- We also offer recommendations for enhancing the efficacy and safety of this approach in future work.
What they did
Pre-clinical and early clinical studies have also highlighted that blocking of inhibitory phagocytic checkpoints, most prominently signal-regulatory protein α (SIRPα) and its ligand CD47, is a promising therapeutic approach for cancer. However, concerns about limited efficacy and toxicities in recent clinical trials have led to diminished enthusiasm for this approach.
Full abstract (original)
Background: The ability of macrophages to eliminate cancer cells through phagocytosis is tightly controlled by pro-phagocytic and inhibitory phagocytic receptors. Pro-phagocytic receptors such as Fc receptors, macrophage-1 antigen (MAC-1; also known as CD11b/CD18) and signalling lymphocytic activation molecule family member 7 (SLAMF7) have been shown to facilitate tumour cell elimination in pre-clinical models, and Fc receptors have been determined critical for the anti-tumour efficacy of several monoclonal antibodies in the clinic.
What they did: Pre-clinical and early clinical studies have also highlighted that blocking of inhibitory phagocytic checkpoints, most prominently signal-regulatory protein α (SIRPα) and its ligand CD47, is a promising therapeutic approach for cancer. However, concerns about limited efficacy and toxicities in recent clinical trials have led to diminished enthusiasm for this approach.
Results & conclusions: In this Review, we examine the evidence supporting phagocytic checkpoints as targets for cancer therapy, while highlighting current challenges associated with this therapeutic strategy. We also offer recommendations for enhancing the efficacy and safety of this approach in future work.
Abstract © the authors / Nature Reviews Cancer (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41568-025-00893-w · PubMed 41360986.
Why it matters for pharma & biotech
- Directly relevant to teams in antibody / ADC therapeutics, targeted oncology / immuno-oncology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: antibody / ADC therapeutics · targeted oncology / immuno-oncology · small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Nature Reviews Cancer study find?
We also offer recommendations for enhancing the efficacy and safety of this approach in future work.
What type of study is this?
It is a review / perspective, published in Nature Reviews Cancer in 2026. Pre-clinical and early clinical studies have also highlighted that blocking of inhibitory phagocytic checkpoints, most prominently signal-regulatory protein α (SIRPα) and its ligand CD47, is a promising therapeutic approach for cancer.
Where can I read the original paper?
The original is at the publisher via DOI 10.1038/s41568-025-00893-w. PubMed ID: 41360986. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/targeting-phagocytosis-checkpoints-for-cancer-immunotherapy-00893w/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides